Hello Alpha, MD-Led Platform

Hello Alpha is an asynchronous telehealth platform founded to give women convenient, affordable access to clinician-guided care for over 100 medical conditions — without the scheduling friction and wait times of traditional primary care. The company launched in California in 2019 and has grown to serve patients across the majority of US states, positioning itself as a membership-based women''s health clinic that patients can use on their own schedule. Weight loss and GLP-1 medications are one of Hello Alpha''s core service lines, alongside birth control, thyroid management, mental health support, and dermatology. The platform''s async model — patients submit intake forms and communicate with providers via secure messaging rather than booking live video calls — appeals to women who find synchronous appointments logistically difficult to fit into daily life. In April 2025, Hello Alpha stopped prescribing compounded semaglutide and tirzepatide in response to FDA guidance on the shortage status of brand-name GLP-1 drugs. The platform now prescribes only FDA-approved brand-name weight loss medications: Wegovy, Zepbound, Saxenda, and, for type 2 diabetes, Ozempic and Mounjaro. This shift prioritizes regulatory compliance but makes cost management more dependent on insurance coverage or manufacturer savings programs. Hello Alpha does not assist with prior authorization for off-label use of diabetes medications — patients who need Ozempic or Mounjaro for obesity without a diabetes diagnosis and without insurance support for weight-loss-indicated drugs should evaluate other platforms. Membership is $79/month (down from higher tiers for basic services) and covers all clinical interactions on the platform. Insurance is not accepted for membership fees or medical visits, though Hello Alpha acknowledges that some pharmacies may accept insurance for brand-name GLP-1 prescriptions. Medicare, Medicaid, and federally funded plans are excluded entirely. Hello Alpha fills a specific gap for women who want a single, asynchronous telehealth home for both GLP-1 weight management and other ongoing health conditions, without the overhead of maintaining separate specialty telehealth subscriptions for each need. For patients whose insurance covers brand-name GLP-1s or who can access manufacturer savings programs, it is a clinically capable and logistically convenient option. The company launched in California in 2019 and has grown to serve patients across the majority of US states, positioning itself as a membership-based women''s health clinic that patients can use on their own schedule. Weight loss and GLP-1 medications are one of Hello Alpha''s core service lines, alongside birth control, thyroid management, mental health support, and dermatology. The platform''s async model — patients submit intake forms and communicate with providers via secure messaging rather than booking live video calls — appeals to women who find synchronous appointments logistically difficult to fit into daily life. In April 2025, Hello Alpha stopped prescribing compounded semaglutide and tirzepatide in response to FDA guidance on the shortage status of brand-name GLP-1 drugs. The platform now prescribes only FDA-approved brand-name weight loss medications: Wegovy, Zepbound, Saxenda, and, for type 2 diabetes, Ozempic and Mounjaro. This shift prioritizes regulatory compliance but makes cost management more dependent on insurance coverage or manufacturer savings programs. Hello Alpha does not assist with prior authorization for off-label use of diabetes medications — patients who need Ozempic or Mounjaro for obesity without a diabetes diagnosis and without insurance support for weight-loss-indicated drugs should evaluate other platforms. Membership is $79/month (down from higher tiers for basic services) and covers all clinical interactions on the platform. Insurance is not accepted for membership fees or medical visits, though Hello Alpha acknowledges that some pharmacies may accept insurance for brand-name GLP-1 prescriptions. Medicare, Medicaid, and federally funded plans are excluded entirely. Hello Alpha fills a specific gap for women who want a single, asynchronous telehealth home for both GLP-1 weight management and other ongoing health conditions, without the overhead of maintaining separate specialty telehealth subscriptions for each need. For patients whose insurance covers brand-name GLP-1s or who can access manufacturer savings programs, it is a clinically capable and logistically convenient option.